Document:

EX-10.5

 Exhibit 10.5 
 AMENDMENT NO. 3 
 TO 

LICENSE AGREEMENT 
 BETWEEN 
 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH

 AND 
 ENTEROMEDICS, INC. 
 This Amendment No. 3 (the
“Amendment No. 3”) is entered into as of Feb 3rd, 2012 (the “Execution Date of Amendment No. 3”) by and between Mayo Foundation for Medical Education and Research, a Minnesota charitable corporation, located at 200 First Street SW,
Rochester, Minnesota 55905-0001 (“MAYO”), and EnteroMedics, Inc., a private for-profit corporation located at 2800 Patton Road, Roseville, Minnesota 55113 (“COMPANY”) and amends that certain License Agreement by and between MAYO
and COMPANY with an Effective Date as of February 3, 2005 (the “License Agreement”) and Amendment No. 1 to the License Agreement with an Execution Date of February 3rd, 2010 (“Amendment No. 1”) and Amendment No. 2 to the License Agreement with an Execution Date of
January 4th, 2011 (“Amendment No. 2”)
with the effect of amending, restating and replacing the following provisions in their entirety with the text set forth below: 
 2.02 MAYO KNOW-HOW COMMITMENT. For a period of five (5) years from the Effective Date for the Obesity Device Group and the Vagal Blocking Device Group and for a period of three (3) years
from the Execution Date of Amendment No. 1 for Michael Camilleri, M.D., Michael Sarr, M.D. and Michael Kendrick of the Phase II Mayo Group and until December 31st, 2010 for William Sandborn, M.D. of the Phase II Mayo Group, unless terminated earlier by either COMPANY or MAYO as
provided for in this Agreement, MAYO commits to the following: 
  

	(a)	Subject to existing obligations to third parties, MAYO policies and for so long as its members are employees of MAYO, the Obesity Device Group shall confer with the
COMPANY in the Field as follows: (i) exclusively for Product Development for devices to treat obesity and nonexclusively for Product Testing; and (ii) non-exclusively for Product Development and Product Testing with COMPANY for Vagal
Devices to treat gastrointestinal disorders other than obesity (for example, pancreatitis and irritable bowel syndrome) and excluding obesity. 

  

	(b)	Subject to existing obligations to third parties, MAYO policies and for so long as its members are employees of MAYO, the Vagal Blocking Device Group shall confer
exclusively with the COMPANY for Product Development and nonexclusively for Product Testing, all for Vagal Devices. 

  

	(c)	 Subject to existing obligations to third parties, MAYO policies and for so long as its members are employees of MAYO, the Phase II Mayo Group shall
confer with the COMPANY in the Field as follows: (i) exclusively for Product Development for Vagal Devices and nonexclusively for Product Development of other devices 

	 	
to treat obesity and nonexclusively for Product Testing; and (ii) non-exclusively for Product Development and Product Testing with COMPANY for Vagal Devices to treat gastrointestinal
disorders other than obesity. 

  

	(d)	Subject to existing obligations to third parties, MAYO hereby grants COMPANY a royalty-bearing, worldwide license to use the Know-How in the Field to develop, make, use
and sell COMPANY Products as provided below: 

 1. With respect to Obesity Device Group Know-How for: 

 

	 	(a)	Product Development, such license shall be exclusive for obesity devices and non-exclusive for Vagal Devices for treating conditions other than obesity; and

  

	 	(b)	Product Testing, such license shall be non-exclusive. 

 2. With respect to the Vagal Blocking Device Group Know-How for: 
  

	 	(a)	Product Development, such license shall be exclusive; and 

  

	 	(b)	Product Testing, such license shall be non-exclusive. 

 3. With respect to the Phase II Mayo Group Know-How for: 
  

	 	(a)	Product Development, such license shall be exclusive for Vagal Devices to treat obesity and nonexclusive for Vagal Devices for treating other conditions other than
obesity; and 

  

	 	(b)	Product Testing, such license shall be non-exclusive. 

 COMPANY shall have the right to sublicense such know-how, but not any obligation of MAYO to confer, on the same terms and conditions as set forth above with respect to Licensed Patents. 

 

	(e)	MAYO represents and warrants that to the best of internal patent counsel’s knowledge as of the Effective Date and without a duty to inquire, MAYO is not aware of
any existing third party obligations that will materially interfere with the Obesity Device Group, the Vagal Blocking Device Group or the Phase II Mayo Group from conferring with COMPANY under Section 2.02, in accordance the terms and
conditions of this Agreement. 

 Each member of the Obesity Device Group, the Vagal Blocking Device Group and the
Phase II Mayo Group shall use reasonable efforts to attend meetings, achieve specific Product Development objectives and milestones, and conduct Product Testing, contributing on average among the individuals of the groups between 3-6 person hours
per month as requested by COMPANY. Any time credited under this Section shall not also be subject to compensation under any other agreement including any agreement referenced under Section 3.14 of this Agreement. 

 3.06 KNOW-HOW RETAINER FEES: The COMPANY shall pay MAYO a minimum annual retainer fee of One Hundred
and Seventy-Five Thousand Dollars (US$175,000) for the Obesity Device Group as partial compensation for its Know-How as specified in the payment schedule below. The COMPANY shall also pay MAYO an additional minimum annual retainer fee of
Seventy-Five Thousand Dollars (US$75,000) for the Vagal Blocking Device Group as partial compensation for its Know-How as specified in the payment schedule below. In 2010, the COMPANY shall pay MAYO a minimum retainer fee of One Hundred Thousand
Dollars (US$100,000) and in 2011 Seventy-Five Thousand Dollars (US$75,000) for the Phase II Mayo Group as partial compensation for its Know-How as specified in the payment schedule below. The following payments shall be made within ten
(10) days of the dates listed: 
  

			
	                        Date	  	 Retainer fee payment due MAYO

	 a) The Effective Date
	  	One Hundred Twenty-Five Thousand Dollars (US$125,000);
	 b) November 1, 2005
	  	One Hundred Twenty-Five Thousand Dollars (US$125,000);
	 c) January 1, 2006
	  	One Hundred Twenty-Five Thousand Dollars (US$125,000);
	 d) July 1, 2006
	  	One Hundred Twenty-Five Thousand Dollars (US$125,000);
	 f) January 1, 2007
	  	Two Hundred Fifty Thousand Dollars (US$250,000);
	 g) January 1, 2008
	  	Two Hundred Fifty Thousand Dollars (US$250,000);
	 h) January 1, 2009
	  	Two Hundred Fifty Thousand Dollars (US$250,000);
	 i) February 15, 2010
	  	One Hundred Thousand Dollars (US$100,000);
	 j) January 1, 2011
	  	Seventy-Five Thousand Dollars (US$75,000); and
	 k) February 3, 2012
	  	Five Hundred Dollars per Hour (US$500/hour) as follows,

 The COMPANY shall pay MAYO a payment of five hundred dollars ($500) per hour in exchange for the Phase II Mayo
Group’s actual time used in providing the Phase II Mayo Group Know-How as requested by the COMPANY. The parties agree that the payment is a good faith estimate of the fair market value for the Phase II Mayo Group’s time used in providing
the Phase II Mayo Group Know-How and, if during performance of providing the Phase II Mayo Group Know-How, in COMPANY’S good faith opinion, the agreed-upon hourly payment for providing such Phase II Mayo Group Know-How to the COMPANY exceeds
the fair market value of the time provided by MAYO, the parties shall negotiate in good faith to reduce the payment for time used to provide the Phase II Mayo Group Know-How to be at fair market value or, in the event the parties do not agree,
COMPANY may terminate the Agreement immediately. The Phase II Group agrees to keep accurate written records (personal records and notes) sufficient in detail to enable COMPANY to determine and verify the fair market value in time used in providing
the Phase II Mayo Group Know-How. Such records for a particular quarter shall be retained by Phase II Mayo Group for a period of not less than one calendar year after the end of such quarter. COMPANY shall have the right, at its own expense and on a
confidential basis, to review such records (or have such records reviewed), at the Phase II Mayo Group members’ offices upon reasonable notice and during reasonable business hours, for the purposes of verifying the payment due Mayo hereunder.
COMPANY or its reviewing designee shall not disclose MAYO’s confidential information without their prior written consent. The Phase II Mayo Group shall provide the Mayo Clinic Ventures a listing of time they contributed to providing Phase II
Mayo Group Know-How to the COMPANY with a brief description of the Phase II Mayo Group Know-How provided. 

 MAYO shall invoice COMPANY for the hours of time incurred by the Phase II Mayo Group in providing the Phase
II Mayo Group Know-How on an individual basis. COMPANY agrees to pay Mayo within thirty (30) days of receiving each such invoice. The payments due under this Agreement shall be nonrefundable. 

Except as expressly amended by this Amendment No. 3, all terms and conditions of the License Agreement as previously amended by Amendment No. 1
and Amendment No. 2 shall remain in full force and effect. 
  

									
	 MAYO FOUNDATION FOR MEDICAL
 EDUCATION AND RESEARCH
	 		 	ENTEROMEDICS, INC.
					
	By:	 	 /s/ Steven P. Van Nurden
	 		 	By:	 	 /s/ Mark B. Knudson

	Name: Steven P. Van Nurden	 		 	Name: Mark B. Knudson
	Title: Assistant Treasurer	 		 	Title: President and CEO
	Date: May 3, 2012	 		 	Date: May 1, 2012EX-10.6

 Exhibit 10.6 
 FIRST AMENDMENT 
 TO 

DISTRIBUTION AGREEMENT 
 This First Amendment (the “First Amendment”), effective as of July 10, 2012 (the “First Amendment Effective Date”) is by and between EnteroMedics, Inc., a Minnesota
corporation located at 2800 Patton Road, St. Paul MN 55113 (“Supplier”), and Device Technologies Australia Pty Limited, located at Unit 8, 25 Frenchs Forest Road, Frenchs Forest, New South Wales 2086 Australia, with ABN 40 058 091 973
(“Distributor”). 
 RECITALS 
 WHEREAS, Supplier and Distributor are Parties to the Distribution Agreement effective as of March 28, 2011 (the “Agreement”); and 

WHEREAS, the Parties desire to amend the Agreement as set forth below. 

NOW THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, the receipt and sufficiency of which is
hereby acknowledged, the parties hereto agree as follows: 
  

	1.	Capitalized terms not otherwise defined herein shall have the same meanings ascribed to them in the Agreement and references to Clauses and Exhibits are to those
Clauses and Exhibits that appear in the Agreement. 

  

	2.	Clause 5.1 is hereby amended and restated in its entirety as follows, with effect as of the earlier of the First Amendment Effective Date or the date of any separate
written agreement of the Parties providing for the same amended terms: 

  

	 	5.1	Delivery 

All deliveries of Products shall be Ex Works (EXW) Supplier’s facility. The term “Ex Works” shall be
construed in accordance with INCOTERMS 2010 of the International Chamber of Commerce. Shipping, insurance, customs duties, etc. are the responsibility of Distributor. Supplier shall have no further responsibility for the Products, and all risk of
damage to or loss or delay of the Products shall pass to Distributor, upon their delivery at the Ex Works delivery point to a common carrier specified by Distributor or, in the event no carrier shall have been specified by Distributor on or before
the date fifteen (15) days prior to the requested shipment date, a common carrier selected by Supplier. Supplier reserves all rights with respect to delivered Products permitted by applicable law until the full amount due from Distributor in
respect of all delivered Products has been paid. Title to the Products shall pass to Distributor upon payment in full in accordance with Clause 6.2 of the Agreement. 

 

	3.	Clause 5.2(b) is hereby amended and restated in its entirety as follows: 

  

	 	(b)	 Distributor will provide Supplier with written notice of any Products which Distributor believes to be defective within 30 days of receipt of the
Products from 

	 	
Supplier. If Distributor receives notice from any customer or other third party that a Product that is not in Distributor’s possession is believed to be defective, which may be at a time
later than thirty (30) days of receipt of the Products from the Supplier, Distributor will retrieve the Product from the customer or other third party promptly upon receiving such notice. Distributor shall hold all Products which are believed
to be defective for Supplier’s instructions for a reasonable period (not exceeding 60 days). If Supplier’s instructions are not received within such period, Distributor may return the defective Products accompanied by a description of the
defect to Supplier’s premises at Supplier’s expense, and any expense incurred by Distributor in such return will be payable forthwith by Supplier and may be set off by Distributor against any moneys otherwise due by Distributor to
Supplier. 

  

	4.	Clause 6.1 is hereby amended and restated in its entirety as follows: 

 The Products are at Distributor’s risk from the time of delivery at the Ex Works delivery point as provided in Clause 5.1 above. 

 

	5.	Clause 7.1(b) is hereby amended and restated in its entirety as follows: 

  

	 	(b)	Distributor shall maintain a database containing details of customers to whom it sells Products during the Term (including the type, quantity and serial numbers of
Products purchased by each customer), and Distributor shall grant Supplier reasonable access to this database upon Supplier’s request. The database shall contain all information which Supplier reasonably determines is necessary to assist
Distributor in recall efforts with regard to the Products in accordance with its obligation under Clause 19 of the Agreement. 

  

	6.	Clause 7.9 is hereby amended and restated in its entirety as follows: 

  

	 	7.9	Sub-Distributors 

 Distributor shall not, without the prior written consent of Supplier, appoint any Sub-Distributors, intermediaries or agents (collectively “Sub-Distributors”) to perform Distributor’s
obligations under this Agreement. Distributor shall at all times remain fully liable for any act or omission of its Sub-Distributors, and Distributor hereby agrees to indemnify, defend and hold harmless Supplier from all damages, losses, liabilities
or expenses arising in any manner from any act or omission on the part of any Sub-Distributor. 
  

	7.	Clause 7.12(f) is hereby amended and restated in its entirety as follows: 

  

	 	(f)	comply with Supplier’s policies for business conduct as provided by Supplier from time to time and/or as posted on Supplier’s website;

  
 2 

	8.	Clause 7.12(i) is hereby amended and restated in its entirety as follows: 

  

	 	(i)	follow the same quality control standards with respect to the storage, preservation, sale and use of the Products as followed by Supplier and communicated to
Distributor by Supplier; store Products according to requirements of Product packaging to ensure maintenance of sterility (when applicable), integrity of packaging and storage in accordance with any environmental conditions, including but not
limited to temperature and humidity requirements; and not remove Products from packages designed for delivery to end-user customers when such removal may affect the quality of the Products or destroy any trademark identity; and

  

	9.	Clause 7.14 is hereby amended by adding the following new Clause 7.14(d): 

 

	 	(d)	Distributor shall at all times comply with all laws and regulations in the Territory applicable to the importation, sale, demonstration, use and disposition of the
Products, including obtaining and maintaining all licenses and permits and satisfying all formalities as may be required under such laws and regulations. 

  

	10.	Clause 8.1(c) is hereby amended and restated in its entirety as follows: 

  

	 	(c)	Distributor shall not use, publish, broadcast or disseminate any advertising and promotional materials without Supplier’s approval. When submitting the materials
to Supplier for approval, Distributor shall give details of when, where and in which medium the materials will be used as well as the target audience of the material. Supplier shall take reasonable steps to promptly respond to Distributor’s
request for approval upon receipt of the materials. 

  

	11.	Clause 9.4 is hereby amended by adding the following new heading and new Clauses 9.4(c), 9.4(d), 9.4(e) and 9.4(f): 

 

	 	9.4	Training, Customer Support, Certification and Product Service 

  

	 	(c)	 Distributor shall have the sole responsibility for (i) obtaining orders for Products from customers, (ii) providing First-Level Support to
customers, (iii) training customers with respect to the Products sold by Distributor, which may also involve training organized by the Supplier, and (iv) handling all other interactions with customers in the Territory with respect to the
Products. Without limiting Distributor’s other obligations in this Clause 9.4, Distributor shall at all times maintain a sufficient level of understanding of the Products to enable Distributor to provide technical information to
customers regarding the Products, to effectively sell and service the Products, and to obtain customer orders and provide assistance to customers in determining and fulfilling their requirements with respect to the Products. For clarity, Supplier
shall have no obligation hereunder to respond to or otherwise interact with any customers in the Territory, although Distributor shall cooperate with Supplier to enable Supplier to have such contacts with customers in the Territory as Supplier
reasonably determines is appropriate consistent with the objectives stated in Clause 9.5. 

  
 3 

	 	
The term “First-Level Support” means a level of support at least at the level designated as required for personnel who are trained and certified in accordance with the Supplier Training
Program described in Clause 9.4(d). 

  

	 	(d)	Distributor personnel shall participate in Supplier’s standard training program applicable to the Products (“Supplier Training Program”) before selling
any Products. The training will be provided at a mutually agreed upon location. Distributor shall be responsible for the travel-related costs and expenses of Supplier’s personnel that attend the Supplier Training Program. Supplier and
Distributor shall mutually agree to the number of Distributor personnel who must attend the Supplier Training Program. 

  

	 	(e)	Distributor shall train all customers with respect to the use of the Products in accordance with the then-current requirements of the Supplier Training Program.
Distributor shall only use training documentation provided by Supplier in performing customer training. Distributor shall create and maintain a record of training for each customer trained by Distributor with respect to the Products in accordance
with a training and accreditation program to be developed and certified by Supplier, and shall provide Supplier with information about such training activities in accordance with report formats to be developed by Supplier. Distributor shall supply
Products only to customers who have satisfactorily completed such Supplier-certified training and accreditation. 

  

	 	(f)	Distributor shall perform all Product service in accordance with the requirements set forth in the Supplier Training Program and otherwise provided by Supplier to
Distributor in writing from time to time during the Term, including requirements regarding customer service response times, and similar matters. Distributor shall document and maintain records of all Product service (“Service Records”) in
accordance with requirements to be developed by Supplier. Distributor shall offer and provide Product service (for Products in and out of warranty) to all customers in the Territory. With respect to out-of-warranty service, Distributor shall warrant
its workmanship with respect to Product service for at least ninety (90) days after completion thereof. Distributor shall, within five (5) days after Supplier’s request, provide Supplier with any or all Service Records.

  

	12.	Clause 9 is hereby amended by adding the following new Clause 9.5: 

  

	 	9.5	Marketing, Promotion, Clinician Training and Clinical Field Support Generally 

Distributor agrees to cooperate with and follow Supplier’s directions during the Term in the development and
execution of regulatory plans; marketing plans; reimbursement approval plans; the identification and accreditation of surgeons, physicians and clinics with appropriate standing to use the Products; surgeon and clinician training protocols; clinical
field support; and the like. The Supplier understands 

  
 4 

 
that the regulatory and reimbursement plans submitted by Distributor will take into account the regulatory and reimbursement requirements in the Territory. In order to achieve these objectives,
Distributor shall use its best efforts to vigorously promote, sell and support the Products throughout the Territory in accordance with such plans, and shall at its cost and expense: (a) employ on its own behalf a sufficient number of
specialized, trained, and qualified personnel to promote, sell and support the Products in the Territory; (b) maintain a professional sales and service organization as necessary to provide training and customer service for the Products in the
Territory; and (c) otherwise operate its business in a professional and ethical manner, in each case in accordance with this Agreement. 
  

	13.	Clause 14.3(e) is hereby amended and restated in its entirety as follows: 

  

	 	(e)	Orders and Post-Termination Sales 

 Supplier shall fulfill all orders from Distributor to Supplier to the extent to which they are unfulfilled at the time of termination or expiration of this Agreement unless Distributor cancels those
orders prior to Delivery of the Products or unless Supplier terminated this Agreement for cause under Clause 14.2. Distributor may use any labels, wraps, containers, advertising and other items bearing the Trademarks to enable it to sell
Products delivered after termination of this Agreement. Distributor shall continue to be obligated to comply with the terms and conditions of this Agreement with regard to any such sales of Products after the termination or expiration of this
Agreement. 
  

	14.	The first lead-in clause of Clause 15 prior to the colon is hereby amended and restated in its entirety as follows: 

If this Agreement is terminated for any reason (including a change of control in the ownership of Supplier or its ultimate
parent company) other than as a result of a breach of this Agreement by Distributor, the occurrence of an event listed in Clause 14.2(b) involving Distributor, termination under Clause 14.2(c)(iv)(A), a force majeure event, or an
Insolvency Event involving Distributor, then Supplier shall, within 60 days of termination of this Agreement provide the following compensation: 
  

	15.	Exhibit A to the Agreement is hereby amended and restated in its entirety as set forth in the attachment to this First Amendment. 

 

	16.	Except as expressly revised and amended herein, the Agreement remains unchanged. Inconsistencies between the Agreement and this First Amendment shall be resolved in
favor of this First Amendment. 

  
 5 

 IN WITNESS WHEREOF, the Parties have executed this First Amendment as of the First
Amendment Effective Date. 
  

									
	ENTEROMEDICS, INC.	 		 	DEVICE TECHNOLOGIES AUSTRALIA PTY LIMITED (ABN 40 058 091 973)
					
	By:	 	 /s/ Mark B. Knudson
	 		 	By:	 	 /s/ Peter J. Ord

	Name:	 	Mark B. Knudson	 		 	Name:	 	Peter J. Ord
	Title:	 	President & CEO	 		 	Title:	 	CEO

  
 6 

 Exhibit A 
 Products 
  

							
	 Model
	  	 Name
	  	 AIMD/MDD Class
	  	 Code description

				
	2004	  	Implant Kit	  	AIMD	  	Implant Kit, Neuroregulator, vagus nerve, rechargeable: An assembly of devices intended to treat obesity through the application of electrical stimuli to the vagus nerve
below the gastric junction. It is typically implanted in the abdomen and consists of a rechargeable battery-operated neuroregulator, implantable lead(s), torque wrench, and components for external charging. The battery is recharged
externally.
				
	2002	  	 Rechargeable
 Neuroregulator
	  	AIMD	  	Neuroregulator, vagus nerve, rechargeable: A device intended to treat obesity through the application of electrical stimuli to the vagus nerve below the gastric junction.
It is typically implanted in the abdomen and consists of a rechargeable battery-operated neuroregulator and torque wrench. The battery is recharged externally.
				
	2200A-47E	  	Anterior Lead	  	III	  	A lead, insulated with non-conductive material except at the electrode(s), that is implanted in the neurological tissue. It is used to make an electrical connection between the
stimulator and the vagus nerve.
				
	2200P-47E	  	Posterior Lead	  	III	  	A lead, insulated with non-conductive material except at the electrode(s), that is implanted in the neurological tissue. It is used to make an electrical connection between the
stimulator and the vagus nerve.

  
 7 

							
	 Model
	  	 Name
	  	 AIMD/MDD Class
	  	 Code description

				
	2403-300	  	Clinician transmit coil	  	III	  	Transmit Coil - An electronic device that provides radio-frequency connection between an implanted Vagus Nerve Electrical Blocking Neuroregulator and an external Mobile
Recharger for transmission of power to charge the battery in the implanted device and to provide information transfer to and from the implant and the Mobile Recharger. This device may be operated by a clinician or patient.
				
	2404	  	Patient kit	  	III	  	Recharging Kit, Neuroregulator, vagus nerve, rechargeable - An assembly of devices used to transcutaneously recharge the battery of a rechargeable implanted
neuroregulator. Typically includes mobile charger, transmit coil, AC recharger and transmit coil belt.
				
	2402	  	Mobile charger	  	III	  	Recharger, Neuroregulator, vagus nerve, rechargeable - A device used to transcutaneously communicate with a rechargeable implanted neuroregulator for recharging the
battery of a rechargeable implanted neuroregulator, or review and modification of neuroregulator operating parameters.
				
	2403-60	  	Patient transmit coil	  	III	  	Transmit Coil - An electronic device that provides radio-frequency connection between an implanted Vagus Nerve Electrical Blocking Neuroregulator and an external Mobile
Recharger for transmission of power to charge the battery in the implanted device and to provide information transfer to and from the implant and the Mobile Recharger. This device may be operated by a clinician or
patient.

  
 8 

							
	 Model
	  	 Name
	  	 AIMD/MDD Class
	  	 Code description

				
	1660	  	Patient transmit coil belt	  	I	  	A device used for keeping electrodes in place. This is typically used for reusable electrodes which do not stick to the body surface or for electrodes that may require extra
securing. This is a reusable device.
				
	2403-60A	  	Patient transmit coil	  	III	  	Transmit Coil - An electronic device that provides radio-frequency connection between an implanted Vagus Nerve Electrical Blocking Neuroregulator and an external Mobile
Recharger for transmission of power to charge the battery in the implanted device and to provide information transfer to and from the implant and the Mobile Recharger. This device may be operated by a clinician or patient.
				
	1660A	  	Patient transmit coil belt	  	I	  	A device used for keeping electrodes in place. This is typically used for reusable electrodes which do not stick to the body surface or for electrodes that may require extra
securing. This is a reusable device.
				
	1620	  	AC recharger	  	I	  	A device designed to supply an electrical charge to rechargeable batteries, restoring the battery to an appropriate working condition. This device is typically connected to the
building’s electrical power supply and can be used to either charge the batteries by themselves (removed from the device) or whilst they are still inside the parent device (in situ), e.g., a defibrillator or ophthalmoscope. This device usually
has current and voltage controls to meet the charge needs of different types of batteries.
				
	1600	  	Programmer cable	  	I	  	A device that provides a connection between two or more devices for the purpose of transmitting an energy that may, or may not, contain
information.

  
 9 

							
	 Model
	  	 Name
	  	 AIMD/MDD Class
	  	 Code description

				
	2504	  	Clinician Programmer Kit	  	III	  	The clinician programmer is a laptop computer with specialized software, which is connected to the mobile charger and transmit coil in order to communicate with the implanted
device. The included programmer cable connects the clinician programmer to the mobile charger. The programmer and cable are intended to be used as part of the Maestro Rechargeable System to configure, monitor and change settings of the implanted
neuroregulator.

  
 10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}]]